KRAS and familial pancreatic carcinoma: Intriguingly, strong Cten expression has been associated with KRAS/BRAF mutations in colorectal cancer, and this association was confirmed as being functionally relevant in colorectal and pancreatic cancers, where Cten has been identified as a downstream target of KRAS signaling [19].